Deerfield Management’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-4,855,005
| Closed | -$73.5M | – | 136 |
|
|
2022
Q3 | $73.5M | Buy |
4,855,005
+159,985
| +3% | +$1.86M | 1.46% | 22 |
|
|
2022
Q2 | $35.2M | Hold |
4,695,020
| – | – | 0.73% | 46 |
|
|
2022
Q1 | $42.7M | Hold |
4,695,020
| – | – | 0.96% | 33 |
|
|
2021
Q4 | $33M | Buy |
4,695,020
+1,718,000
| +58% | +$18M | 0.69% | 43 |
|
|
2021
Q3 | $33.9M | Buy |
2,977,020
+2,151,083
| +260% | +$31.4M | 0.66% | 45 |
|
|
2021
Q2 | $13.2M | Buy |
825,937
+331,721
| +67% | +$5.69M | 0.23% | 100 |
|
|
2021
Q1 | $8.83M | Sell |
494,216
-667,817
| -57% | -$11.5M | 0.19% | 106 |
|
|
2020
Q4 | $15.7M | Buy |
1,162,033
+667,817
| +135% | +$8.07M | 0.31% | 82 |
|
|
2020
Q3 | $5.82M | Hold |
494,216
| – | – | 0.14% | 94 |
|
|
2020
Q2 | $7.29M | Sell |
494,216
-2,037,931
| -80% | -$30.1M | 0.21% | 82 |
|
|
2020
Q1 | $34.2M | Buy |
2,532,147
+759,892
| +43% | +$14.4M | 1.08% | 30 |
|
|
2019
Q4 | $42.8M | Sell |
1,772,255
-2,796,569
| -61% | -$57.9M | 1.37% | 27 |
|
|
2019
Q3 | $87.8M | Buy |
4,568,824
+1,535,837
| +51% | +$35.2M | 3.58% | 7 |
|
|
2019
Q2 | $89.6M | Buy |
3,032,987
+1,424,202
| +89% | +$54.9M | 3.22% | 7 |
|
|
2019
Q1 | $76.4M | Buy |
1,608,785
+90,189
| +6% | +$3.97M | 2.93% | 8 |
|
|
2018
Q4 | $54.8M | Sell |
1,518,596
-21,852
| -1% | -$1.03M | 2.19% | 12 |
|
|
2018
Q3 | $94.8M | Buy |
1,540,448
+1,056,393
| +218% | +$67.9M | 3.4% | 5 |
|
|
2018
Q2 | $32.7M | Hold |
484,055
| – | – | 1.15% | 31 |
|
|
2018
Q1 | $26.3M | Hold |
484,055
| – | – | 0.91% | 42 |
|
|
2017
Q4 | $28.9M | Sell |
484,055
-148,631
| -23% | -$9.01M | 1.14% | 33 |
|
|
2017
Q3 | $30.7M | Sell |
632,686
-328,461
| -34% | -$17.9M | 1.39% | 24 |
|
|
2017
Q2 | $50.5M | Buy |
961,147
+165,404
| +21% | +$7.7M | 2.69% | 10 |
|
|
2017
Q1 | $36.1M | Sell |
795,743
-1,043,086
| -57% | -$46.5M | 1.39% | 24 |
|
|
2016
Q4 | $69.6M | Buy |
1,838,829
+500,000
| +37% | +$18.9M | 2.86% | 7 |
|
|
2016
Q3 | $50.5M | Sell |
1,338,829
-1,181,756
| -47% | -$26.1M | 2.35% | 15 |
|
|
2016
Q2 | $44.4M | Sell |
2,520,585
-111,897
| -4% | -$1.81M | 1.74% | 17 |
|
|
2016
Q1 | $32M | Buy |
2,632,482
+1,824,607
| +226% | +$28.9M | 1.36% | 26 |
|
|
2015
Q4 | $19.7M | Hold |
807,875
| – | – | 0.8% | 43 |
|
|
2015
Q3 | $14.3M | Sell |
807,875
-1,403,769
| -63% | -$25.4M | 0.55% | 57 |
|
|
2015
Q2 | $39M | Buy |
2,211,644
+1,605,526
| +265% | +$29.4M | 1.3% | 21 |
|
|
2015
Q1 | $19M | Sell |
606,118
-1,252,799
| -67% | -$36.3M | 0.62% | 43 |
|
|
2014
Q4 | $54.3M | Sell |
1,858,917
-466,000
| -20% | -$11.8M | 1.95% | 16 |
|
|
2014
Q3 | $48.1M | Buy |
2,324,917
+974,067
| +72% | +$19.2M | 1.75% | 17 |
|
|
2014
Q2 | $33.5M | Buy |
1,350,850
+785,670
| +139% | +$13.6M | 1.35% | 24 |
|
|
2014
Q1 | $12M | Buy |
565,180
+265,180
| +88% | +$5.36M | 0.49% | 56 |
|
|
2013
Q4 | $5.39M | Buy |
+300,000
| New | +$3.91M | 0.28% | 74 |
|
Deerfield Management's AERI Position: Q4 2022 in Review
Deerfield Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 4,855,005 shares — an estimated $73.5M sold.
Deerfield Management first reported a position in AERI in Q4 2013 and held it in 36 quarters. The position peaked at $94.8M in Q3 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Deerfield Management reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Deerfield Management sold 4,855,005 Aerie Pharmaceuticals shares in Q4 2022, an estimated $73.5M.
- Deerfield Management first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 36 quarters.
- Deerfield Management's Aerie Pharmaceuticals position peaked at $94.8M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Deerfield Management's 13F filing for Q4 2022, filed 14 Feb 2023.